Intravenous Magnesium in Patients Receiving Cisplatin
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This research study, is trying to determine the highest dose of magnesium that can be given
safely to people with malignant mesothelioma receiving intraoperative chemotherapy with
cisplatin who are at risk for acute kidney injury.
The name(s) of the study drug involved in this study is
- magnesium sulfate.